NasdaqGS:ENTABiotechs
Enanta Pharmaceuticals (ENTA) Quarterly Loss Narrows Yet Keeps Profitability Concerns In Investor Focus
Enanta Pharmaceuticals Q1 2026 Earnings Snapshot
Enanta Pharmaceuticals (ENTA) opened its 2026 financial year with Q1 revenue of US$18.6 million and a basic EPS loss of US$0.42, alongside a net income loss of US$11.9 million, setting a clear tone for where the business is today. The company has seen quarterly revenue fluctuate in a tight band between US$14.6 million and US$18.6 million over the last six reported periods, while basic EPS losses have ranged from about US$0.42 to US$1.36. This...